NCT05313074 is a NA clinical trial of CoronaVac vaccine in COVID-19, sponsored by National Cancer Institute, Thailand.

Who is sponsoring NCT05313074?

NCT05313074 is sponsored by National Cancer Institute, Thailand.

What drugs are being tested in NCT05313074?

Interventions in NCT05313074: CoronaVac vaccine.

What condition does NCT05313074 study?

NCT05313074 studies COVID-19, Cancer.

Is NCT05313074 still recruiting?

NCT05313074 is currently completed. Last updated 15 April 2022.

Last reviewed 2022-04-15 · How we verify

NCT05313074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

Completed NA Last updated 15 April 2022

What this trial tests

NA trial testing CoronaVac vaccine in COVID-19 in 311 participants. Completed in 25 February 2022.

Timeline

23 March 2021

Primary endpoint
25 February 2022

25 February 2022

Quick facts

Lead sponsor	National Cancer Institute, Thailand
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	311
Start date	23 March 2021
Primary completion	25 February 2022
Estimated completion	25 February 2022
Sites	1 location across Thailand

Drugs / interventions tested

CoronaVac vaccine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Cancer — all drugs for Cancer →

Sponsor

National Cancer Institute, Thailand

Who can join

18 and older, any sex, with COVID-19 or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CoronaVac vaccine

Trials testing the same drug.

NCT05599555 — Community-based Sero-epidemiological Study of COVID-19 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05313074 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Thailand
Last refreshed: 15 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05313074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing